Oncomine Dx Express Test Gains FDA Approval, Expanding Thermo Fisher’s Precision Oncology Portfolio
July 17, 2025
The FDA approval of Thermo Fisher’s Oncomine Dx Express Test marks a key advancement in precision oncology, enabling fast, accurate detection of EGFR exon 20 insertion mutations and guiding NSCLC patients to targeted treatments like ZEGFROVY.
